Your session is about to expire
← Back to Search
Ruxolitinib cream for Hand Eczema (TRuE-CHE1 Trial)
TRuE-CHE1 Trial Summary
This trial will test whether ruxolitinib cream can improve symptoms of moderate to severe chronic hand eczema.
- Hand Eczema
TRuE-CHE1 Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTRuE-CHE1 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TRuE-CHE1 Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Can middle-aged adults participate in this research?
"Eligibility for this particular trial is restricted to individuals aged 18 to 99. Out of the total of 206 clinical trials, 87 are for those under 18 years old and 119 are for seniors over the age of 65."
Are there multiple locations participating in this research project in the city?
"Patients can be enrolled at any of the 32 locations for this trial, which include Progressive Clinical Research in San Antonio, Texas, Center For Clinical Studies Webster in Webster, California, and First Oc Dermatology in Fountain Valley, Louisiana."
Has the cream version of Ruxolitinib been cleared by the FDA?
"Ruxolitinib cream is currently being trialled in Phase 3 clinical trials, which means that while there is some data supporting its efficacy, there is also multiple rounds of data supporting its safety. As such, our team at Power have given it a safety rating of 3."
Are there any specific medical requirements to participate in this research?
"This clinical trial is seeking 180 participants that suffer from eczema. The individuals must be between 18-99 years old and meet the following criteria: a diagnosis of chronic hand eczema, recent history of inadequate response to treatment with topical corticosteroids or topical calcineurin inhibitors, or oral alitretinoin, and a willingness to avoid pregnancy or fathering children."
Share this study with friends
Copy Link
Messenger